

Figure 1. Biologically active pyrazole derivatives.



Scheme 1. Synthesis of pyrazole derivatives **4a-c**, **6a-c, 8** and **10a-c;** reagents and conditions: (a) EtOH/Et_3N, heat 1 h (b) EtOH/Et_3N, heat 1 h (c) EtOH/Et_3N, heat 2h (d) EtOH/Et_3N, heat 1 h



Scheme 2. Synthesis of pyrazole derivatives **12-14** and **17a-c;** reagents and conditions: (a) 1,4 dioxane/Et_3N, heat 2 h (b) EtOH/Et_3N, heat 2 h (c) EtOH/Et_3N, heat 2 h (d) EtOH/Et_3N, heat 1 h



Scheme 3. Synthesis of pyrazole derivatives **19**, **20**, **22a-d**.; reagents and conditions: (a) fusion 120 C, 30 min (b) EtOH/Et_3N, heat 2 h (c) 1,4-dioxane/Et_3N, heat 3 h



Scheme 4. Synthesis of pyrazole derivatives **25a-c,** reagents and conditions: (a) DMF/KOH, r.t. (b) r.t. overnight



Figure 2. Cytotoxicity of compounds **4a-c**, **6a-c**, **8**, **10a-c** and CHS 828 against NUGC, gastric cancer; DLDI, colon cancer; HA22Tand HEPG2, liver cancer; HONEI, nasopharyngeal carcinoma; MCF, breast cancer.



Figure 3. Cytotoxicity of compounds **12, 13**, **14**, **17a-c**, **19**, **20** and CHS 828 against NUGC, gastric cancer; DLDI, colon cancer; HA22T and HEPG2, liver cancer; HONEI, nasopharyngeal carcinoma; MCF, breast cancer.



Figure 4. Cytotoxicity ofcompounds **22a-d**, **25a-c** and CHS 828 against NUGC, gastriccancer; DLDI, colon cancer; HA22T and HEPG2, liver cancer; HONEI, nasopharyngeal carcinoma; MCF, breast cancer